Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $28,719 | $37,189 |
| Research and development related success payments and contingent consideration | 8,433 | 1,957 |
| General and administrative | 11,462 | 11,484 |
| Total operating expenses | 48,614 | 50,630 |
| Loss from operations | (48,614) | (50,630) |
| Interest income, net | 951 | 992 |
| Other income, net | 453 | 249 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's G&A?
- Sana Biotechnology (SANA) reported G&A of $11.46M in Q1 2026.
- How has Sana Biotechnology's G&A changed year-over-year?
- Sana Biotechnology's G&A decreased by 0.2% year-over-year, from $11.48M to $11.46M.
- What is the long-term trend for Sana Biotechnology's G&A?
- Over 4 years (2021 to 2025), Sana Biotechnology's G&A has grown at a -3.2% compound annual growth rate (CAGR), from $50.41M to $44.3M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Sana Biotechnology's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude